Cidara Therapeutics, Inc. (CDTX) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001610618

P/B 9.08

P/E -20.76

P/S 0.00

Market Cap 3.83 Bn

ROIC (Qtr) -42.13

Div Yield % 0.00

Rev 1y % (Qtr) 0.00

Total Debt (Qtr) 1.98 Mn

Debt/Equity (Qtr) 0.00

About

Cidara Therapeutics, Inc., a prominent player in the biotechnology industry, is dedicated to the development of targeted therapies designed to save lives and improve the standard of care for patients grappling with serious diseases. The company's operations primarily revolve around the discovery, development, and commercialization of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. Cidara Therapeutics' main business activities encompass the biotechnology industry, a highly competitive...

Cidara Therapeutics, Inc., a prominent player in the biotechnology industry, is dedicated to the development of targeted therapies designed to save lives and improve the standard of care for patients grappling with serious diseases. The company's operations primarily revolve around the discovery, development, and commercialization of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system.

Cidara Therapeutics' main business activities encompass the biotechnology industry, a highly competitive and rapidly evolving field. The company's primary competitors include other biotechnology companies, pharmaceutical companies, and research institutions that are also developing novel therapies for serious diseases. Cidara Therapeutics' strategic partnerships and collaborations with these entities are crucial in accelerating the development and commercialization of its products.

The company's revenue generation is primarily driven by its partnerships and collaborations, as well as funding from government agencies and private investors. Cidara Therapeutics' financial performance is anticipated to continue improving as its products advance through clinical trials and receive approvals for commercialization.

Cidara Therapeutics' product portfolio includes REZZAYO, a once-weekly echinocandin antifungal for the treatment and prevention of invasive fungal infections, and CD388, a DFC for the prevention and treatment of seasonal and pandemic influenza. The company's Cloudbreak platform facilitates the development of novel DFCs that can target multiple immune checkpoint pathways within a single DFC for oncologic indications.

REZZAYO, developed by Melinta Therapeutics, LLC, a subsidiary of Cidara Therapeutics, is a promising treatment option for patients with invasive fungal infections. Its once-weekly dosing regimen and long half-life make it a convenient and effective treatment option for patients. The product has the potential to generate significant revenue for Cidara Therapeutics and its partners.

The Cloudbreak Influenza Program is a research and development initiative focused on developing novel DFCs for the prevention and treatment of seasonal and pandemic influenza. The program, based on Cidara Therapeutics' Cloudbreak platform, is currently in Phase 1 and Phase 2a clinical trials, in collaboration with Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson.

The Cloudbreak Oncology Programs are another research and development initiative focused on developing novel DFCs for the treatment of solid tumor cancers. The program, based on the company's Cloudbreak platform, is in various stages of development and being developed in collaboration with WuXi XDC, a leading global contract manufacturing organization.

Cidara Therapeutics has established a robust intellectual property portfolio, with numerous patents and patent applications related to its products and technology. The company's strong position within the industry is attributed to its innovative Cloudbreak platform and a robust pipeline of products in development, as well as its proven track record of success in clinical trials.

Stock Price Chart

Analysis

Pros

Healthy cash reserves of 299.99M provide 192.30x coverage of short-term debt 1.56M, demonstrating strong liquidity position and minimal refinancing risk.
Robust free cash flow of (132.75M) exceeds capital expenditure of (185000) by 717.59x, indicating strong organic growth funding capability.
Strong tangible asset base of 518.65M provides 261.42x coverage of total debt 1.98M, indicating robust asset backing and low credit risk.
Long-term investments of 50.16M provide solid 118.30x coverage of long-term debt 424000, indicating strategic financial planning.
Short-term investments of 126.37M provide solid 1.41x coverage of other current liabilities 89.93M, indicating strong liquidity.

Cons

Operating cash flow of (132.94M) barely covers its investment activities of (176.28M), with a coverage ratio of 0.75, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
Investment activities of (176.28M) provide weak support for R&D spending of 131.82M, which is -1.34x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
The company's operating cash flow of (132.94M) shows concerning coverage of stock compensation expenses of 9.53M, with a -13.96 ratio indicating potential earnings quality issues.
Operating earnings of (184.74M) show weak coverage of depreciation charges of 1.40M, with a -131.67 ratio indicating high capital intensity and potential reinvestment needs.
Operating cash flow of (132.94M) barely covers operating expenses of 35.55M with a -3.74 ratio, suggesting thin operational efficiency margins and limited flexibility.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SMMT	Summit Therapeutics Inc.	1,349.40 Bn	-1,464.17	0.00	0.01 Bn
2	ONC	BeOne Medicines Ltd.	437.43 Bn	6,381.20	87.97	1.90 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	116.09 Bn	31.59	9.90	1.83 Bn
4	REGN	Regeneron Pharmaceuticals, Inc.	78.10 Bn	17.06	5.48	2.71 Bn
5	ALNY	Alnylam Pharmaceuticals, Inc.	55.87 Bn	1,282.42	17.40	3.21 Bn
6	ARGX	Argenx Se	52.85 Bn	35.08	27,559.65	-
7	BNTC	Benitec Biopharma Inc.	41.75 Bn	-998.33	0.00	0.00 Bn
8	INSM	INSMED Inc	37.80 Bn	-31.93	84.56	0.74 Bn

Industry Comparisons

Current Valuation

Metric	Value	Industry
EV to Assets	6.40	12.31
EV to Cash from Ops.	-24.97	23.25
EV to Debt	1,673.43	738.44
EV to EBIT	-17.97	-9.16
EV to EBITDA	-17.11	6.95
EV to Free Cash Flow [EV/FCF]	-25.01	21.90
EV to Market Cap	0.87	65.67
EV to Revenue	0.00	227.32
Price to Book Value [P/B]	9.08	22.34
Price to Earnings [P/E]	-20.76	-11.77

Dividend Metrics

Metric	Value	Industry	Percentile
Dividend Coverage Ratio	0.00	-11.94
Dividend Payout Ratio %	0.00	0.16
Dividend per Basic Share	0.00	0.01
FCF Dividend Payout Ratio %	0.00	-0.14
Interest Coverage	0.00	841.00

Growth Metrics

Metric	Value	Industry
Capex Growth (1y) %	160.26	-27.13
Cash and Equivalents Growth (1y) %	135.50	734.65
Dividend Growth (1y) %	0.00	0.01
EBIAT Growth (1y) %	-53.01	-46.93
EBITDA Growth (1y) %	-49.98	-1.68
EBIT Growth (1y) %	-53.02	-56.45
EBT Growth (1y) %	-53.02	-12.70
EPS Growth (1y) %	58.17	-28.31
FCF Growth (1y) %	17.10	-31.90
Gross Profit Growth (1y) %	0.00	226.84

Liquidity Ratios

Metric	Value	Industry
Asset Utilization Ratio	0.00	0.14
Cash Payout Ratio	0.00	0.00
Cash Ratio	3.13	3.85
Current Ratio	4.62	7.27
Debt to Equity Ratio	0.00	0.40
Interest Cover Ratio	0.00	841.00
Times Interest Earned	0.00	841.00

Profitability

Metric	Value	Industry	Percentile
EBITDA Margin %	0.00	-18,234.31
EBIT Margin %	0.00	-18,580.80
EBT Margin %	0.00	-19,488.74
Gross Margin %	0.00	-7.59
Net Profit Margin %	0.00	-19,439.22

Cidara Therapeutics, Inc. (NASDAQ: CDTX)